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Introduction: Cinacalcet has proved effective to control secondary hyperparathyroidism in
patients on haemodialysis (HD). Some studies have reported an appropriate secondary
hyperparathyroidism control and a better compliance after intradialytic use of calcimimet-
ics.
Objectives: To assess the effect of post-dialysis calcimimetics use on mineral bone disorders
and  calcimimetics gastrointestinal tolerability in our HD unit.
Material and methods: A 12-week single-centre prospective study in HD patients treated with
cinacalcet (>2 months). Two study periods: usual outpatient use (Stage 1) and use after HD
session (Stage 2). Endpoints: (1) biochemical MBD data; (2) Gastrointestinal Symptom Rating
Scale (GSRS) for gastrointestinal tolerability, and visual analogic scale (VAS) for satisfaction;
(3)  adherence: Morisky–Green test (MG) and ﬁnal tablet count (TC).
Results: Sixty-two HD patients. Fourteen received cinacalcet (22.5%). TEN patients were
included, mean age was 60.9 years; patients had received HD for 80.9 months. Mean Charl-
son index: 9. Biochemical data: Stage 1 (initial vs. ﬁnal): Ca 8.8 ± 0.5 mg/dl vs. 9.1 ± 0.7 mg/dl
(P  < 0.05); P 5.2 ± 0.8 mg/dl vs. 4.5 ± 1.6 mg/dl, iPTH 360.3 ± 232.7 pg/ml vs. 349 ± 122 pg/ml.
MG:  70%. Stage 2 (initial vs. ﬁnal): Ca 9.1 ± 0.7 mg/dl vs. 8.8 ± 0.6 mg/dl; P 4.5 ± 1.6 mg/dl vs.
4.6  ± 1.3 mg/dl, iPTH 360.3 ± 232.7 pg/ml vs. 349 ± 122 pg/ml. TC: 89%. GSRS and VAS were bet-
ter in Stage 2 (GSRS 7.5 ± 5.2 vs. 4.3 ± 1.9; VAS 4.8 ± 2.3 vs. 6.9 ± 2.8). No signiﬁcant changes
were  observed in calcimimetic dose (201 mg/week vs. 207 mg/week), number of phosphate
binders (9 pts/day vs. 8.2 pts/day), native vitamin D (70% vs. 60%), selective vit D receptor
activators (30%), or suitable dialysis parameters.
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Conclusions: Post-dialysis use of calcimimetic was effective in secondary hyper-
parathyroidism control, improved gastrointestinal tolerability and ameliorated patients’
satisfaction. Based on our ﬁndings, post-dialysis use of calcimimetics should be considered
in  selected patients with low therapeutic compliance.
©  2015 Sociedad Espan˜ola de Nefrología. Published by Elsevier España, S.L.U. This is an
open  access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
Administración  de  calcimiméticos  posdiálisis:  igual  efectividad,  mejor
tolerancia  gastrointestinal
Palabras clave:
Hemodiálisis
Calcimiméticos
Hiperparatiroidismo secundario
r  e  s  u  m  e  n
Introducción: Cinacalcet resulta efectivo en el control del hiperparatiroidismo secundario
de  los pacientes en hemodiálisis (HD). Algunos estudios han reportado un buen control del
hiperparatiroidismo secundario y un mejor cumplimiento terapéutico tras la administración
de  calcimiméticos intradiálisis.
Objetivos: Analizar el efecto de la administración de calcimiméticos posdiálisis sobre el
metabolismo óseo mineral y la tolerancia gastrointestinal en nuestra unidad de HD.
Material y métodos: Estudio prospectivo unicéntrico de 12 semanas de duración en pacientes
en  HD tratados con cinacalcet (> 2 meses). Dos períodos de estudio (6 semanas): Adminis-
tración habitual ambulatoria (fase 1) y posthemodiálisis (fase 2). Datos analizados: 1.- Datos
bioquímicos metabolismo óseo mineral. 2.-Test síntomas gastrointestinales (Gastrointesti-
nal Symptom Rating Scale [GSRS]) y grado de satisfacción (escala visual analógica [EVA]).
3.-Adherencia: Test de Morisky-Green (MG) y recuento ﬁnal comprimidos (RC).
Resultados: Sesenta y dos pacientes en HD. Catorce recibían cinacalcet (22,5%). Diez pacientes
incluidos, edad media 60,9 an˜os y 80,9 meses en HD. Charlson medio: 9. Datos bioquími-
cos:  fase 1 (inicio vs. ﬁn): Ca 8,8 ± 0,5 vs. 9,1 ± 0,7 mg/dl (p < 0,05); fósforo 5,2 ± 0,8 vs.
4,5  ± 1,6 mg/dl, PTHi 353 ± 129 vs. 360 ± 232 pg/ml. Adherencia (MG): 70%. Fase 2 (inicio
vs.  ﬁn): Ca 9,1 ± 0,7 vs. 8,8 ± 0,6 mg/dl; fósforo 4,5 ± 1,6 vs. 4,6 ± 1,3 mg/dl; PTHi 3603 ± 2327
vs.  349 ± 122 pg/ml. Adherencia (RC): 89%. Con relación al GSRS y el grado de satisfacción,
fueron mejores en la fase 2 (GSRS 7,5 ± 5,2 vs. 4,3 ± 1,9; EVA 4,8 ± 2,3 vs. 6,9 ± 2,8). No se obje-
tivaron cambios signiﬁcativos en la dosis de calcimiméticos (201 vs. 207 mg/sem), número
captores fósforo (9 vs. 8,2 pac/día), vitamina D nativa (70 vs. 60%) o activadores selectivos
receptor vitD (30%), ni en los parámetros de adecuación dialítica.
Conclusiones: La administración de calcimiméticos post diálisis permitió controlar el hiper-
paratiroidismo secundario de forma eﬁcaz, mejorando la sintomatología gastrointestinal y
el  grado de satisfacción. Se debe considerar la administración de calcimiméticos post diálisis
en  aquellos pacientes con escaso cumplimiento terapéutico.
© 2015 Sociedad Espan˜ola de Nefrología. Publicado por Elsevier España, S.L.U. Este es un
artículo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/Introduction
Chronic kidney disease (CKD) is an important public health
problem, due to its high prevalence as well as its signiﬁcant
cardiovascular morbidity and mortality and socioeconomic
cost.1,2
The prevalence of CKD is around 10% in the general pop-
ulation, and it is higher in those older than 64 years. Around
1–1.5% require renal replacement therapy, in most cases with
haemodialysis (HD).3–5
The aims of treatment are directed at reducing and treating
the complications associated with CKD such as anaemia and
secondary hyperparathyroidism. Strong association has been
shown between these disturbances and an increased rate of
cardiovascular events and pathological fractures.6–9licenses/by-nc-nd/4.0/).
Hypocalcaemia, vitamin D (calcitriol) deﬁciency, and build-
up of phosphorus levels in patients with CKD are some of the
multiple factors that stimulate synthesis of parathyroid hor-
mone (PTH), leading to proliferation of the parathyroid glands
and various bone and systemic abnormalities. Currently, there
is a broad range of drugs to control this pathological pro-
cess, including phosphate binders, native vitamin D, vitamin
D-receptor-selective analogues, and calcimimetics.10–12
The mechanism of action of calcimimetics is to increase
the sensitivity of the calcium-sensing receptor that is located
on the surface of the chief cells of the parathyroid glands,
thus reducing serum concentration of PTH, calcium, and
phosphorus.13–15The use of calcimimetics is indicated in cases of uncon-
trolled secondary hyperparathyroidism in which optimum
levels of PTH are not achieved despite administration of
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hosphate binders or vitamin D. Calcimimetics have a high
ost, are given orally, and are dispensed from hospital,
herefore patients must periodically attend to collect the
rug from their reference hospital. The main adverse effects
re gastrointestinal, principally in the form of nausea and
omiting associated with high doses used for control of
yperparathyroidism.16–18
Bearing in mind the characteristics of patients with CKD
n HD and all the details associated with the administration
f calcimimetics, it is not difﬁcult to understand that there
s poor treatment adherence and difﬁcult control of hyper-
arathyroidism, with its associated consequences.
There are few, very limited, previous studies available in the
iterature that have analysed the effectiveness of supervised,
ntradialytic administration of calcimimetics. Those studies
btained results of good control of secondary hyperparathy-
oidism without signiﬁcant adverse effects, as well as better
reatment adherence.19–21
This study aims to assess the effect of supervised post-
ialysis administration of calcimimetics in our HD unit on
ontrol of abnormal bone mineral metabolism and gastroin-
estinal tolerance, our intention is the achievement of better
reatment adherence with less side effects.
aterials  and  methods
his was a prospective single-centre observational study of
2 weeks’ duration in patients on a HD programme in our
entre, carried out between November 2012 and February
013. It was approved by the ethics committee and per-
ormed in accordance with the standards of the declaration of
elsinki.
The inclusion criteria were being on a HD programme in our
nit for at least 2 months prior to enrolment, receiving treat-
ent with calcimimetics at least 2 months prior to enrolment,
nd giving informed consent. The exclusion criteria were sus-
ained hypocalcaemia (<8.8 mg/dL) after correcting for serum
lbumin, or not giving informed consent.
There were two study phases, of 6 weeks’ duration each.
n the ﬁrst phase (phase 1), the enrolled patients received
reatment with a calcimimetic prescribed according to routine
linical practice (to be taken daily as an outpatient), which was
ollected by the patient at the pharmacy service in our hospi-
al. In the second phase (phase 2), the calcimimetic was given
t the end of each HD session (3 times per week) under nurse
upervision, with no changes to the total dose prescribed in
hase 1, and no need to attend the hospital pharmacy. The
alcimimetic tablets used were 30 and 60 mg.  All prescribed
ablets were kept and stored by HD nursing staff. The daily
oses for 1 one week were added to get the weekly dose
mg/week), which was then divided in 3 for administration
t the end of the HD session, aiming to give the fewest tablets
ossible. For example, if the dose to be given was 210 mg/week
30 mg/day), it was divided in the following way: ﬁrst day, 60 mg
1 tablet); second day, 60 mg  (1 tablet); and third day, 90 mg
1 tablet of 60 mg  and 1 tablet of 30 mg). The highest dose was
lways given on the last day of HD.
The main demographic and biochemical variables related
o bone mineral metabolism were collected, as were variables(4):403–409 405
regarding adequacy and characteristics of HD at the start and
end of each phase of the study, coinciding with the routine
scheduled follow-up tests for HD patients.
Regarding treatment with calcimimetics, information was
collected on the weekly dose (mg/week), the usual time of
administration, and the length of time on treatment (months).
Information was also collected on the number of tablets and
types of phosphate binders (calcium binders, non-calcium
binders, aluminium hydroxide), vitamin D receptor-selective
analogues, and native vitamin D.
In the third week of each phase, we evaluated gastroin-
testinal tolerance and level of satisfaction. For gastrointestinal
tolerance, the Gastrointestinal Symptom Rating Scale (GSRS)
was used as an assessment tool. This scale contains 15 items
divided into 5 groups with different gastrointestinal symp-
toms. The 5 groups of symptoms are reﬂux, abdominal pain,
diarrhoea, indigestion, and constipation. It contains a Likert-
type scale of 7 marks, with 1 being the post positive option and
7 being the most negative option. For assessment of the level
of satisfaction, a visual analogue scale was used, with scores
and visual representation between 0 (least satisﬁed) and 10
(most satisﬁed).
Treatment adherence was evaluated at the start of phase
1 using the Morinsky-Green test. This is an indirect method
of evaluating treatment adherence using a self-questionnaire
of 4 questions. It evaluates if the patient adopts a correct atti-
tude regarding treatment. To be considered good adherence,
the response to all questions must be adequate. At the end of
phase 2, treatment adherence was evaluated by counting the
number of tablets administered.
Statistical analysis was performed using the programme
SPSS version 180 (SPSS Inc., Chicago, IL, USA). Quantitative
variables were expressed as mean and standard deviation.
Qualitative variables were expressed as percentage. The com-
parison of quantitative data was done using Wilcoxon test for
nonparametric related variables, and the comparison of qual-
itative data was done using McNemar test. A P value <.05 was
considered statistically signiﬁcant.
Results
We  analysed 62 patients on a HD programme in our HD unit, of
whom 14 (22.5%) were receiving treatment with calcimimet-
ics (cinacalcet); 10 patients were enrolled and 4 patients were
excluded (1 due to a psychiatric disorder and 3 due to time
on treatment being <2 months). 40% were men, and the
mean age was 60.9 ± 14.1 years. Mean time on HD was 80.9 ±
114.9 months. The main cause of CKD in our patients was dia-
betes mellitus, in 40%; the other causes are shown in Fig. 1. The
mean Charlson comorbidity index score was 9 ± 4.2. The mean
cinacalcet dose was 201 ± 155 mg/week and the mean duration
of previous cinacalcet use was 23.7 ± 20.5 months. None of our
patients had known previous gastrointestinal disease.Bone  mineral  metabolism
The main biochemical data on bone mineral metabolism are
shown in Table 1.
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Table 1 – Main biochemical data on bone mineral metabolism. Phase 1 and phase 2 of the study.
Phase 1 Phase 2
Start End SS Start End SS
Ca (mg/dL) 8.8 ± 0.5 9.1 ± 0.7 0.045* 9.1 ± 0.7 8.8 ± 0.6 0.049*
P (mg/dL) 5.2 ± 0.8 4.5 ± 1.6 0.270 4.5 ± 1.6 4.6 ± 1.3 0.766
Ca × P (mg/dL)2 45.7 ± 0.4 40.9 ± 11.2 0.652 40.9 ± 11.2 40.48 ± 7.81 0.983
iPTH (pg/mL) 353 ± 129 360 ± 232 0.929 360 ± 232 350 ± 122 0.880
Ca, calcium; Ca ± P, calcium–phosphorus product; P, phosphorus; iPTH, intact parathyroid hormone; SS, statistical signiﬁcance.
∗ P < .05.In phase 1, serum calcium increased signiﬁcantly (start vs.
end: Ca 8.8 ± 0.5 mg/dL vs. 9.1 ± 0.7 mg/dL, P = .045). There were
no relevant changes in phosphorus values (P 5.2 ± 0.8 mg/dL
vs. 4.5 ± 1.6 mg/dL, P = .270) or intact parathyroid hormone
(iPTH 353 ± 129 pg/mL vs. 360 ± 232 pg/mL, P = .929). In phase
2, serum calcium decreased signiﬁcantly (start vs. end:
Ca 9.1 ± 0.7 mg/dL vs. 8.8 ± 0.6 mg/dL, P = .049). As with the
ﬁrst phase, there were no relevant changes in phospho-
rus values (P 4.5 ± 1.6 mg/dL vs. 4.6 ± 1.3 mg/dL, P = .766) or
intact parathyroid hormone (iPTH 360.3 ± 232.7 pg/mL vs.
349 ± 122 pg/mL, P = .880). Likewise, there were no relevant
changes in the values of serum albumin (39 ± 4.9 mg/dL vs.
38.4 ± 3.85 mg/dL, P = .678), serum alkaline phosphatase (ALP
151.2 ± 148.8 mg/dL vs. 155.3 ± 162 mg/dL, P = .515), magne-
sium (Mg  2.44 ± 0.52 mg/dL vs. 2.44 ± 0.54 mg/dL, P = .472), or
native vitamin D (36.49 ± 19.26 ng/mL vs. 37.22 ± 10.44 ng/mL,
P = .861) throughout the study.
In both phases there were no signiﬁcant changes in
the mean total dose of cinacalcet (201 ± 155 mg/week vs.
207 ± 151 mg/week; P = 0.816), or in the number of phosphate
binders (9 binders/patient/day vs. 8.2 binders/patient/day,
P = .678) or type of phosphate binders (85% calcium binders,
40% non-calcium binders, 15% aluminium, in both phases
respectively), or in the percentage use of native vitamin D (70%
CTINGlomerOthersDM
20%
20%
20%
40%
Fig. 1 – Primary causes of CKD. Percentage of patients
on HD treated with calcimimetics. CTIN, chronic
tubulointerstitial nephropathy; DM,  diabetes mellitus;
Glomer, glomerular.vs. 60%) or selective vitamin D analogues (30% in both phases).
There were no differences in the parameters of dialysis ade-
quacy (Daugirdas second gen Kt/V: 1.69 ± 0.26 vs. 1.71 ± 0.27,
P = .649) or in the HD characteristics (calcium bath: 2.5 mEq/L,
20%; 3 mEq/L, 50%; and 3.5 mEq/L, 30% in both phases).
Gastrointestinal  tolerance  and  level  of  satisfaction
Severity of gastrointestinal symptoms improved signiﬁcantly
in patients treated with supervised cinacalcet at the end of
the HD session (phase 1 vs. phase 2 GSRS, 7.5 ± 5.2 vs. 4.3 ± 1.9,
P = .011). In the analysis of the different aspects of GSRS, there
was a lower scoring in all aspects, fundamentally due to lack
of diarrhoea and indigestion, though it was not statistically
signiﬁcant (Table 2). There were no changes in consump-
tion of antacid medications or gastric protectors throughout
the study (90% in both phases). All patients completed the
study.
There was also a higher scoring for level of satisfaction,
using the visual scale (4.8 ± 2.3 vs. 6.9 ± 2.8; P = .021), in patients
who received supervised cinacalcet treatment at the end of the
HD session.
Treatment  adherenceIn phase 1, using the Morisky–Green test, treatment adherence
was 70%. In phase 2, using counting of tablets, adherence was
89% (245 tablets administered/276 prescribed).
Table 2 – Evaluation of gastrointestinal symptoms (GSRS)
and level of satisfaction (VAS).
Start End SS
GSRS 7.5 ± 5.2 4.3 ± 1.9 0.011*
Reﬂux 0.6 ± 0.2 0.2 ± 0.2 0.487
Abdominal pain 1.6 ± 0.3 1 ± 0.4 0.335
Constipation 1.5 ± 0.3 1.4 ± 0.3 0.235
Diarrhoea 1.6 ± 0.2 0.6 ± 0.2 0.085
Indigestion 2.2 ± 0.4 1.1 ± 0.4 0.074
VAS 4.8 ± 2.3 6.9 ± 2.8 0.021*
GSRS, Gastrointestinal Symptom Rating Scale; SS, statistical signiﬁ-
cance; VAS, visual analogue scale. Average score (1–5) of symptoms
according to the different categories. Start vs. end: GSRS categories:
reﬂux, abdominal pain, constipation, diarrhoea, and indigestion.
∗ P < .05.
1 5;3  5
D
I
c
t
a
s
r
w
a
s
a
2
C
c
u
c
a
i
c
t
a
i
(
t
t
p
c
p
i
c
n
a
p
r
b
w
w
e
t
e
s
T
s
s
v
f
t
a
w
g
t
p
w
m
v
dn e f r o l o g i a. 2 0 
iscussion
n our patients, supervised intermittent administration of
alcimimetics after dialysis sessions was effective in con-
rol of secondary hyperparathyroidism. In the literature, there
re recent studies that have assessed the effectiveness of
upervised intradialytic administration of calcimimetics, with
esults of good control of secondary hyperparathyroidism
ithout signiﬁcant adverse effects, and better treatment
dherence.
Al Hilali et al.19 saw a similar effect in PTH suppres-
ion after administration of calcimimetics twice per week
fter dialysis, compared with a daily regimen, in a group of
7 patients on a HD programme. Likewise, Haq and
haaban20,21 observed that post-dialysis administration of
inacalcet was as effective as the standard daily home sched-
le in a group of 11 patients, after 16 weeks of follow-up. In
ontrast to the aforementioned studies, our study did not have
 comparison group, there were no changes to the treatments
nvolved in hyperparathyroidism control or in the dialysis
haracteristics, and also, our patients had previously received
reatment with calcimimetics. Although it is true that with
 higher treatment compliance there would be an expected
mprovement in values of bone mineral metabolism control
above all calcaemia and iPTH), in our study we  saw statis-
ically signiﬁcant changes only in serum calcium values in
he different phases, with no changes in the values of phos-
horus and iPTH. Regarding the difference in serum Ca, this
ould have been due to incomplete taking of calcimimetics in
hase 1, and correct treatment compliance with calcimimetics
n phase 2. The absence of signiﬁcant changes in iPTH values
ould be attributed in part to use of one isolated value and
ot average values of iPHT, as well as the great variability in
verage values in a small sample that is analysed with a non-
arametric test. However, in both study phases, our patients
emained within the therapeutic targets of the guidelines on
one mineral metabolism from various nephrology societies,
ithout changes in the total doses administered. Therefore,
e  interpret that the 2 patterns of administration are equally
ffective in the control of secondary hyperparathyroidism.
Many  medications have adverse effects that can contribute
o their irregular consumption. The gastrointestinal side
ffects of calcimimetics are widely known, the most common
ymptoms being nausea (21–43%) and vomiting (13–30%).11,12
aking medications at night or with food are some of the
trategies used to minimise those adverse effects.22–25 In our
tudy, gastrointestinal symptoms improved after the super-
ised post-dialysis administration of calcimimetics. This was
undamentally due to the symptoms of diarrhoea and indiges-
ion, which were reduced by up to 50%. These ﬁndings were
ttributed to the intermittent taking of the medications, which
ere not taken for a total of 4 days per week, thus avoiding the
astrointestinal upset associated with a daily dose. Regarding
his, the low dose prescribed in our patients (most of the
atients received a regular dose no more  than 60 mg/day) as
ell as the routine intradialytic ingestion of food, could have
inimised gastrointestinal symptoms. In fact, under super-
ised administration, our patients received higher individual
oses than they had routinely been prescribed, and there(4):403–409 407
were no discontinuations due to gastrointestinal intolerance
during the study. Furthermore, during the supervised post-
dialysis administration, the level of satisfaction improved
signiﬁcantly. This ﬁnding could be explained ﬁrstly by
the reduction in gastrointestinal symptoms, and secondly
by the simple fact that patients avoided the inconvenience of
collecting medications at the hospital pharmacy in our cen-
tre, which is located away from the dialysis unit and has
opening hours that do not always coincide with routine HD
sessions. Following the results of our study, we  will consider
post-dialysis administration in patients with difﬁculty attend-
ing the hospital pharmacy (due to either physical condition or
scheduled HD time).
As previously mentioned, patients on HD have a high drug
load, due to their associated increased concomitant condi-
tions, which can result in poor treatment adherence. The
average rate of treatment compliance in randomised con-
trolled studies in patients with CKD on a HD programme is
around 42–78% and is getting lower over time.26–30 In our study,
the adherence rate is similar to that previously published.
As expected, with supervised post-dialysis administration,
treatment compliance improved, despite the use of different
methods of evaluating treatment compliance in the differ-
ent phases of the study. The Morisky–Green test is widely
used in various population studies of therapeutic inertia and
compliance, particularly in the setting of the hypertensive
population. It was used in phase 1 to maintain neutrality, to
avoid factors of confusion and subsequent interpretation (for
example, encouraging the taking of medications in supposedly
noncompliant patients). In phase 2, in order to be objective,
it was decided to use the ﬁnal count of cinacalcet tablets to
calculate the total quantity and number of tablets of medica-
tion used. However, despite supervision by a nurse, treatment
nonadherence was 11%. This fact could be attributable to an
oversight of the nursing staff in administering the medica-
tion in the ﬁnal moments of disconnecting the patients, when
there are other care tasks to be done; or possible errors in
the number of tablets to administer after the HD session (for
example 2 tablets instead of 3). Perhaps using a single admin-
istration schedule, or taking the medication at another point
in the HD session could minimise this mild nonadherence,
although the end of the HD session was chosen to ensure the
same moment for taking the medication for all patients in
phase 2 and to avoid errors in assessment of gastrointesti-
nal symptoms (because of intradialytic food), as well as to not
coincide with the administration of other regular medications
by nursing staff during HD sessions.
One point to highlight in our study is that it was car-
ried out according to routine clinical practice. That is to say
that in current practice, despite the medical indications, it
is not uncommon to give low doses of calcimimetics on
alternate days, thanks to recent improvements in the con-
trol of secondary hyperparathyroidism. Among the multiple
limitations of our study, some of which have already been
mentioned, the most notable were the low number of patients,
requiring the use of a non-parametric statistical test, and
the short follow-up time in our patients; though a period
of 12 weeks was chosen to avoid potential changes in reg-
ular medications associated with bone mineral metabolism
after routine 3-monthly tests. Regrettably, it was not possible
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to do a cost-economic analysis. Studies with more  patients
and a longer duration would be needed to conﬁrm the
effectiveness and gastrointestinal tolerance of calcimimetics
given under supervision post-HD, in the control of secondary
hyperparathyroidism.
In conclusion, in our study, supervised post-dialysis admin-
istration of calcimimetics was effective in the control of
secondary hyperparathyroidism, with fewer gastrointesti-
nal effects and a higher level of satisfaction. Based on
these results, we  consider the administration of post-dialysis
calcimimetics to be effective and, above all, beneﬁcial in deter-
mined patients with poor treatment compliance.
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